Literature DB >> 7568827

Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate.

J Pruim1, A T Willemsen, W M Molenaar, A van Waarde, A M Paans, M A Heesters, K G Go, G M Visser, E J Franssen, W Vaalburg.   

Abstract

PURPOSE: Positron emission tomography (PET) with the amino acid tracer L-[1-C-11]-tyrosine was evaluated in 27 patients with primary and recurrent brain tumors.
MATERIALS AND METHODS: Patients underwent either static (n = 14) or dynamic PET (n = 13), with quantification of protein synthesis rate (PSR) and tumor-to-background ratio. Findings were compared with histologic findings.
RESULTS: Primary brain tumor was proved in 22 patients histologically, as well as metastatic cancer of unknown origin, primary non-Hodgkin lymphoma, meningioma, atypical infarction, and vasculitis in one patient each. At PET, 20 of 22 primary tumors, the metastasis, and non-Hodgkin lymphoma were correctly depicted. A false-positive finding was obtained with the infarction, and the meningioma and vasculitis were not depicted. The calculated sensitivity was 92%; specificity, 67%; and accuracy, 89%. There were no statistically significant relationships between histologic findings, PSR, and tumor-to-background ratio.
CONCLUSION: L-[1-C-11]-tyrosine is a valid tracer for diagnosis of brain tumors and allowed quantification of PSR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7568827     DOI: 10.1148/radiology.197.1.7568827

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  11 in total

Review 1.  Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?

Authors:  B J Schaller; M Modo; M Buchfelder
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

Review 2.  Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview.

Authors:  Punit Sharma; Anirban Mukherjee
Journal:  Ann Transl Med       Date:  2016-02

3.  Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma.

Authors:  Yoshihiro Nishiyama; Yuka Yamamoto; Toshihide Monden; Yasuhiro Sasakawa; Nobuyuki Kawai; Katashi Satoh; Motoomi Ohkawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-29       Impact factor: 9.236

Review 4.  Positron emission tomography in patients with primary CNS lymphomas.

Authors:  U Roelcke; K L Leenders
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

Review 5.  Developing biomarker-specific end points in lung cancer clinical trials.

Authors:  Joel W Neal; Justin F Gainor; Alice T Shaw
Journal:  Nat Rev Clin Oncol       Date:  2014-12-23       Impact factor: 66.675

6.  Evaluation of Glycolytic Response to Multiple Classes of Anti-glioblastoma Drugs by Noninvasive Measurement of Pyruvate Kinase M2 Using [18F]DASA-23.

Authors:  Corinne Beinat; Chirag B Patel; Yuanyang Xie; Sanjiv S Gambhir
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

7.  Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.

Authors:  Gabriele Pöpperl; Claudia Götz; Walter Rachinger; Franz-Josef Gildehaus; Jörg-Christian Tonn; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-10       Impact factor: 9.236

8.  Gliomatosis cerebri evaluated by 18Falpha-methyl tyrosine positron-emission tomography.

Authors:  N Sato; T Inoue; K Tomiyoshi; J Aoki; N Oriuchi; A Takahashi; T Otani; H Kurihara; T Sasaki; K Endo
Journal:  Neuroradiology       Date:  2003-09-13       Impact factor: 2.804

Review 9.  Imaging tumor metabolism using positron emission tomography.

Authors:  David Y Lewis; Dmitry Soloviev; Kevin M Brindle
Journal:  Cancer J       Date:  2015 Mar-Apr       Impact factor: 3.360

10.  Uptake of AV-1451 in meningiomas.

Authors:  Tyler J Bruinsma; Derek R Johnson; Ping Fang; Matthew Senjem; Keith A Josephs; Jennifer L Whitwell; Bradley F Boeve; Mukesh K Pandey; Kejal Kantarci; David T Jones; Prashanthi Vemuri; Melissa Murray; Jonathan Graff-Radford; Christopher G Schwarz; David S Knopman; Ronald C Petersen; Clifford R Jack; Val J Lowe
Journal:  Ann Nucl Med       Date:  2017-09-08       Impact factor: 2.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.